CRISPR Therapeutics Management
Management Kriterienprüfungen 3/4
CRISPR Therapeutics' CEO ist Sam Kulkarni , ernannt in Dec 2017, hat eine Amtszeit von 6.5 Jahren. Die jährliche Gesamtvergütung beträgt $12.32M , bestehend aus 5.9% Gehalt und 94.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.48% der Aktien des Unternehmens, im Wert von $25.22M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.7 Jahre bzw. 5 Jahre.
Wichtige Informationen
Sam Kulkarni
Geschäftsführender
US$12.3m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 5.9% |
| Amtszeit als Geschäftsführer | 6.5yrs |
| Eigentum des Geschäftsführers | 0.5% |
| Durchschnittliche Amtszeit des Managements | 4.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5yrs |
Jüngste Management Updates
Recent updates
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18
Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
Vergütung im Vergleich zum Markt: SamDie Gesamtvergütung ($USD12.32M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD8.44M).
Entschädigung vs. Einkommen: SamDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sam Kulkarni (46 yo)
6.5yrs
Amtszeit
US$12,322,196
Vergütung
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman | 6.5yrs | US$12.32m | 0.48% $ 25.2m | |
| Chief Financial Officer | 1.3yrs | US$5.91m | 0.012% $ 618.1k | |
| General Counsel & Secretary | 7.1yrs | US$3.51m | 0.072% $ 3.8m | |
| Founder | no data | keine Daten | keine Daten | |
| Co-Founder & Scientific Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Chief Operating Officer | less than a year | keine Daten | 0.012% $ 630.1k | |
| Head of Technical Operations | 4.7yrs | keine Daten | keine Daten | |
| Vice President of Corporate Communications & Investor Relations | no data | keine Daten | keine Daten |
4.7yrs
Durchschnittliche Betriebszugehörigkeit
49yo
Durchschnittliches Alter
Erfahrenes Management: CRSPDas Führungsteam des Unternehmens gilt als erfahren (4.7 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman | 6yrs | US$12.32m | 0.48% $ 25.2m | |
| Co-Founder & Scientific Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Scientific Founder & Advisory Board Member | no data | keine Daten | keine Daten | |
| Lead Independent Director | 4yrs | US$552.56k | 0.0024% $ 123.8k | |
| Independent Director | 9.2yrs | US$545.06k | 0.00032% $ 16.8k | |
| Independent Director | 5yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9.2yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 5yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 3yrs | US$536.24k | 0% $ 0 |
5.0yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrener Vorstand: CRSPDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).